Daniëlle Verver

Daniëlle Verver is a Researcher in the Department of Surgery at Erasmus MC, actively contributing to clinical and translational oncology research with a strong focus on melanoma and surgical pathology. Her work bridges surgical practice with molecular and immunological evaluation of cancer progression and treatment response.

Research Interests: Her primary research areas include melanoma biology, sentinel node analysis, gene expression profiling for risk stratification, immunotherapeutic responses, and surgical management of skin and breast cancers. She also investigates patient experiences and unmet needs in melanoma survivorship, integrating psychosocial dimensions into oncological care.

The recent publications demonstrate a consistent trend in translational melanoma research, combining clinicopathological data with molecular insights to improve patient outcomes. Her work on the CP-GEP model and talimogene laherparepvec highlights efforts in personalized oncology and immunotherapy evaluation. Additionally, her research extends to benign and high-risk breast lesions, reflecting a broader interest in surgical oncology and minimally invasive techniques.

Scientific Output: She has authored or co-authored multiple peer-reviewed articles in high-impact journals such as Cancers, Melanoma Research, and British Journal of Radiology. Her collaborative network includes leading researchers in dermatology, surgical oncology, and pathology at Erasmus MC.

Advising and Grants: While no formal students or grant funding are mentioned in the available text, her involvement in multi-center and multidisciplinary studies suggests active participation in research teams and potential mentorship roles. Further information would be needed to confirm supervisory activities or independent funding.

Labs and Teams: Daniëlle Verver is embedded within the surgical oncology and dermatological research ecosystem at Erasmus MC, collaborating closely with experts in melanoma treatment, pathology, and immunotherapy. She contributes to teams focused on improving diagnostic accuracy, treatment efficacy, and patient-centered care in oncology.